Printer Friendly

BIOGEN REPORTS FOURTH QUARTER AND 1991 RESULTS

 BIOGEN REPORTS FOURTH QUARTER AND 1991 RESULTS
 CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Biogen, Inc.


(NASDAQ: BGEN) today reported financial results for the year and quarter ending Dec. 31, 1991.
 For the three months ending Dec. 31, 1991, the company reported revenues of $17,601,000 compared to revenues in the same quarter of 1990 of $16,128,000. For the full year, Biogen reported its third consecutive profitable year with earnings per share of 15 cents after preferred dividends, compared to 7 cents per share in 1990. Total revenues were $69,577,000 for 1991 which represent a 17 perent increase over the prior year. Royalty revenues, which were 81 percent of revenues, grew 26 percent over last year.
 Biogen's revenues continue to reflect significant royalites from the worldwide sales of alpha interferon Intron A(R) and the company's various hepatitis B products. The company expects additional growth once Intron A is approved for treating chronic hepatitis B patients. Royalties from the sales of hepatitis B diagnostics and vaccines also increased, with additional growth anticipated due to the recently announced formal recommendation from the Centers for Disease Control for universal childhood immunization against hepatitis B.
 Jim Vincent, Biogen chairman and chief executive officer, commented, "1991 was an important year for Biogen as the efforts that we have put into the development of our proprietary products have begun to produce significant results. Both of our proprietary drugs, hirulog and beta interferon, made significant progress in the clinic. Hirulog, which has been undegoing Phase II testing for several cardiovascular indications, has demonstrated excellent efficacy and safety profiles in trials involving over 500 patients. We also remain optimistic about beta interferon," Vincent continued, "which is in Phase II clinical trials for a number of indications, including hepatitis B and C, as well as Phase III multi-center trial for multiple sclerosis."
 "1992 will be a critical year for Biogen as we embark upon the largest clinical program in the company's history," Vincent concluded. "Hirulog will enter Phase III clinical trials, numerous Phase II beta trials will be completed and we will be preparing to move a product candidate from our inflammation program in diet clinics.
 Biogen, Inc., headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human health care through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon, hepatitis vaccines and hepatitis diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS, and certain cancers.
 BIOGEN, INC.
 Financial Results for the Fourth Quarter and Full Year 1991:
 (Amounts in thousands, except per share data)
 Three Months Ended Year Ended
 12/31/90 12/31/91 12/31/90 12/31/91
 Revenues:
 Royalties and
 product sales $13,238 $14,698 $44,920 $56,477
 Research &
 development contracts 553 750 5,145 4,965
 Interest 2,337 2,153 9,350 8,135
 Total revenues 16,128 17,601 59,415 69,577
 Expenses:
 Cost of sales 822 1,384 3,020 4,033
 Research & development 9,001 11,929 36,158 44,292
 General & admin. 2,484 3,639 10,109 14,328
 Other 1,122 (353) 2,118 (522)
 Total expenses 13,429 16,599 51,405 62,131
 Income before
 income taxes 2,699 1,002 8,010 7,446
 Income taxes 124 --- 290 260
 Net Income $2,575 $1,002 $7,720 $7,186
 Preferred dividends $1,467 --- $5,865 $2,679
 Net income
 available to common $1,108 $1,002 $1,855 $4,507
 Net income per share 4 cents 3 cents 7 cents 15 cents
 Average number of
 shares outstanding 26,043 33,225 25,430 29,964
 -0- 1/15/92R
 /CONTACT: Amy D. Seltzer of Biogen, 617-252-9200/
 (BGEN) CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: ERN


SH -- NE010R -- 0169 01/15/92 16:25 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 1992
Words:657
Previous Article:GLOBAL HEALTH SCIENCES FUND INITIAL PUBLIC OFFERING
Next Article:NOVA CORPORATION OF ALBERTA SIGNS UNDERWRITING AGREEMENT
Topics:


Related Articles
SYNTEX ESTIMATES FOURTH QUARTER RESULTS
BIOGEN REPORTS THIRD QUARTER EARNINGS OF 33 CENTS PER SHARE
BIOGEN REPORTS FOURTH QUARTER AND 1992 RESULTS
BIOGEN REPORTS YEAR-TO-DATE EARNINGS OF $0.82 PER SHARE ON REVENUES OF $110.6 MILLION
BIOGEN REPORTS FOURTH QUARTER AND 1993 RESULTS
BIOGEN REPORTS $25 MILLION CHARGE TO EARNINGS IN Q3
BIOGEN REPORTS REVISED FOURTH QUARTER AND 1994 RESULTS
BIOGEN REPORTS FIRST QUARTER RESULTS
BIOGEN REPORTS FOURTH QUARTER AND 1995 RESULTS
Biogen Reports First Quarter 1997 Results And Commencement Of New Clinical Trials

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters